Role of pattern and multifocal electroretinogram for macular evaluation in patients with multiple sclerosis treated with fingolimod

Objective To detect the role of pattern electroretinogram (PERG) and multifocal electroretinogram (MfERG) for macular function evaluation in patients with relapsing–remitting multiple sclerosis (RR-MS) treated by fingolimod. Patients and methods This prospective research was carried out on 25 patien...

Full description

Saved in:
Bibliographic Details
Main Authors: Randa H. Abdelgawad, Yasmine Z. Abdel Wadood, Mohamed Y.S. Seif, Mahmoud A. Sultan, Dina A. Zamzam, Safaa A.M. Aboud
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-01-01
Series:Journal of the Egyptian Ophthalmological Society
Subjects:
Online Access:https://journals.lww.com/10.4103/ejos.ejos_59_24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1825199263866421248
author Randa H. Abdelgawad
Yasmine Z. Abdel Wadood
Mohamed Y.S. Seif
Mahmoud A. Sultan
Dina A. Zamzam
Safaa A.M. Aboud
author_facet Randa H. Abdelgawad
Yasmine Z. Abdel Wadood
Mohamed Y.S. Seif
Mahmoud A. Sultan
Dina A. Zamzam
Safaa A.M. Aboud
author_sort Randa H. Abdelgawad
collection DOAJ
description Objective To detect the role of pattern electroretinogram (PERG) and multifocal electroretinogram (MfERG) for macular function evaluation in patients with relapsing–remitting multiple sclerosis (RR-MS) treated by fingolimod. Patients and methods This prospective research was carried out on 25 patients with RR-MS (50 eyes), treated by fingolimod, with no ophthalmic disorders or complaints before the onset of the treatment, including no history of optic neuritis. PERG, MfERG, and spectral domain optical coherence tomography were performed before then 3 and 6 months after the treatment. Results Best-corrected visual acuity (BCVA) significantly decreased in third and sixth months compared to baseline (P<0.001). Central macular thickness showed nonsignificant change. PERG waveform abnormalities were detected in 2.5% of patients at third month (P=0.9) and 27.5% in sixth month (P<0.001). PERG P50 amplitude nonsignificantly decreased in third month (P=0.6), then significantly decreased at sixth month (P=0.021). PERG N95 amplitude showed no significant difference (P=0.345). MfERG revealed nonsignificant decrease of P1 amplitude of all five rings at third and sixth months. The duration of MS had significant negative correlations with BCVA, amplitude, and amplitude change of P1 of both ring 1 and ring 2. Conclusion Treatment with fingolimod for 6 months led to a significant reduction in BCVA and PERG responses and a slight decrease in P1 amplitude of MfERG before detection of any structural macular changes by optical coherence tomography. This indicates the role of PERG and MfERG as biomarkers for the early detection of macular function alteration in RR-MS fingolimod-treated cases.
format Article
id doaj-art-6cc575df014f40b788d44f95769f91f4
institution Kabale University
issn 2090-0686
language English
publishDate 2025-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of the Egyptian Ophthalmological Society
spelling doaj-art-6cc575df014f40b788d44f95769f91f42025-02-08T05:27:16ZengWolters Kluwer Medknow PublicationsJournal of the Egyptian Ophthalmological Society2090-06862025-01-011181778710.4103/ejos.ejos_59_24Role of pattern and multifocal electroretinogram for macular evaluation in patients with multiple sclerosis treated with fingolimodRanda H. AbdelgawadYasmine Z. Abdel WadoodMohamed Y.S. SeifMahmoud A. SultanDina A. ZamzamSafaa A.M. AboudObjective To detect the role of pattern electroretinogram (PERG) and multifocal electroretinogram (MfERG) for macular function evaluation in patients with relapsing–remitting multiple sclerosis (RR-MS) treated by fingolimod. Patients and methods This prospective research was carried out on 25 patients with RR-MS (50 eyes), treated by fingolimod, with no ophthalmic disorders or complaints before the onset of the treatment, including no history of optic neuritis. PERG, MfERG, and spectral domain optical coherence tomography were performed before then 3 and 6 months after the treatment. Results Best-corrected visual acuity (BCVA) significantly decreased in third and sixth months compared to baseline (P<0.001). Central macular thickness showed nonsignificant change. PERG waveform abnormalities were detected in 2.5% of patients at third month (P=0.9) and 27.5% in sixth month (P<0.001). PERG P50 amplitude nonsignificantly decreased in third month (P=0.6), then significantly decreased at sixth month (P=0.021). PERG N95 amplitude showed no significant difference (P=0.345). MfERG revealed nonsignificant decrease of P1 amplitude of all five rings at third and sixth months. The duration of MS had significant negative correlations with BCVA, amplitude, and amplitude change of P1 of both ring 1 and ring 2. Conclusion Treatment with fingolimod for 6 months led to a significant reduction in BCVA and PERG responses and a slight decrease in P1 amplitude of MfERG before detection of any structural macular changes by optical coherence tomography. This indicates the role of PERG and MfERG as biomarkers for the early detection of macular function alteration in RR-MS fingolimod-treated cases.https://journals.lww.com/10.4103/ejos.ejos_59_24fingolimodmultifocal electroretinogrampattern electroretinogramoptical coherence tomographyelapsing–remitting multiple sclerosis
spellingShingle Randa H. Abdelgawad
Yasmine Z. Abdel Wadood
Mohamed Y.S. Seif
Mahmoud A. Sultan
Dina A. Zamzam
Safaa A.M. Aboud
Role of pattern and multifocal electroretinogram for macular evaluation in patients with multiple sclerosis treated with fingolimod
Journal of the Egyptian Ophthalmological Society
fingolimod
multifocal electroretinogram
pattern electroretinogram
optical coherence tomography
elapsing–remitting multiple sclerosis
title Role of pattern and multifocal electroretinogram for macular evaluation in patients with multiple sclerosis treated with fingolimod
title_full Role of pattern and multifocal electroretinogram for macular evaluation in patients with multiple sclerosis treated with fingolimod
title_fullStr Role of pattern and multifocal electroretinogram for macular evaluation in patients with multiple sclerosis treated with fingolimod
title_full_unstemmed Role of pattern and multifocal electroretinogram for macular evaluation in patients with multiple sclerosis treated with fingolimod
title_short Role of pattern and multifocal electroretinogram for macular evaluation in patients with multiple sclerosis treated with fingolimod
title_sort role of pattern and multifocal electroretinogram for macular evaluation in patients with multiple sclerosis treated with fingolimod
topic fingolimod
multifocal electroretinogram
pattern electroretinogram
optical coherence tomography
elapsing–remitting multiple sclerosis
url https://journals.lww.com/10.4103/ejos.ejos_59_24
work_keys_str_mv AT randahabdelgawad roleofpatternandmultifocalelectroretinogramformacularevaluationinpatientswithmultiplesclerosistreatedwithfingolimod
AT yasminezabdelwadood roleofpatternandmultifocalelectroretinogramformacularevaluationinpatientswithmultiplesclerosistreatedwithfingolimod
AT mohamedysseif roleofpatternandmultifocalelectroretinogramformacularevaluationinpatientswithmultiplesclerosistreatedwithfingolimod
AT mahmoudasultan roleofpatternandmultifocalelectroretinogramformacularevaluationinpatientswithmultiplesclerosistreatedwithfingolimod
AT dinaazamzam roleofpatternandmultifocalelectroretinogramformacularevaluationinpatientswithmultiplesclerosistreatedwithfingolimod
AT safaaamaboud roleofpatternandmultifocalelectroretinogramformacularevaluationinpatientswithmultiplesclerosistreatedwithfingolimod